<a href="https://www.medchemexpress.com/Afuresertib.html">Afuresertib</a>產(chǎn)品描述:Afuresertib is an orally available, ATP-competitive, <b>pan-AKT</b> inhibitor with <b>K<sub>i</sub></b> of 0.08, 2 and 2.6 nM against <b>AKT1</b>, <b>AKT2</b> and <b>AKT3</b>, respectively.IC50 & Target: Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)<sup>[1]</sup><br/>IC50: 0.2 nM (AKT1<sup>E17K</sup>), 1.3 nM (PKA), 0.9 nM (PKG1α), 4 nM (PKG1β)<sup>[1]</sup><i><b>In Vitro:</b></i> Afuresertib (GSK2110183) shows concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3β, PRAS40, FOXO and Caspase 9 in both BT474 and LNCaP cell lines. GSK2110183 consistently has potent anti-proliferative effects on a variety of hematological malignancies. Overall 65% of the hematological cell lines are sensitive to GSK2110183 (EC<sub>50</sub><1 µM). Among solid tumor cell lines, 21% have EC<sub>50</sub><1 µM in response to GSK2110183<sup>[1]</sup>. <i><b>In Vivo:</b></i> Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK<br><br><br><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動(dòng)劑、API及化合物庫(kù),總部位于美國(guó)新澤西,分別在瑞典和上海設(shè)有歐洲區(qū)子公司和亞洲區(qū)總代理,營(yíng)銷網(wǎng)點(diǎn)遍及全球20多個(gè)國(guó)家地區(qū)。MCE經(jīng)過(guò)多年努力已成為全球生物活性小分子領(lǐng)域的一流供應(yīng)商, 產(chǎn)品涵蓋癌癥、神經(jīng)科學(xué)、抗感染、表觀遺傳學(xué)等20個(gè)熱門研究領(lǐng)域,PI3K、MAPK等近千個(gè)細(xì)分靶點(diǎn),超過(guò)4000個(gè)活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過(guò)20種不同類型的化合物庫(kù),同時(shí)提供從毫克到千克的專業(yè)定制合成服務(wù)。</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對(duì)每批產(chǎn)品都進(jìn)行嚴(yán)格的LCMS和NMR檢驗(yàn),其產(chǎn)品已被全球近萬(wàn)名客戶廣泛使用并發(fā)表大量文章、專利;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領(lǐng)域熱門抑制劑、激動(dòng)劑,不斷擴(kuò)增已有化合物庫(kù),以滿足最新的科研需求;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時(shí)內(nèi)送達(dá)客戶;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產(chǎn)品提供免費(fèi)試用裝;</span><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">已為全球多個(gè)知名企業(yè)、院校構(gòu)建各種定制型化合物庫(kù)。</span><br><br>產(chǎn)品鏈接:<a href="http://www.medchemexpress.cn/afuresertib.html">www.medchemexpress.cn/afuresertib.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
Afuresertib研究進(jìn)展
發(fā)布日期:2017-10-31 瀏覽次數(shù):0
核心提示:a href=https://www.medchemexpress.com/Afuresertib.htmlAfuresertib/a產(chǎn)品描述:Afuresertib is an orally available, ATP-com
- 下一篇:暫無(wú)
- 上一篇:CDDO-Im研究進(jìn)展
行業(yè)動(dòng)態(tài)
更多...
- Afuresertib研究進(jìn)展 10-31
- CDDO-Im研究進(jìn)展 10-31
- Vercirnon研究進(jìn)展 10-31
- NSC 23766研究進(jìn)展 10-31
- SB-222200研究進(jìn)展 10-31
- FH535研究進(jìn)展 10-31
- H-1152 (dihydrochloride) 10-31
- H-1152研究進(jìn)展 10-31
- NU 7026研究進(jìn)展 10-31
- Istaroxime (hydrochlorid 10-31